Imatinib (IMTB), a first-generation tyrosine kinase inhibitor, that is used to treat chronic myeloid leukemia has however been implicated in hepatic injury. Linalool is a natural monoterpene alcohol with strong biologic antioxidant property. This study investigated the hepatoprotective potential of linalool against imatinib-induced toxicity in male BALB/c mice. 30 male BALB/c mice were randomly divided into five groups: I, control; II, olive oil (0.1ml olive oil); III, IMTB (400 mg/kg b.w.); IV, IMTB (400 mg/kg B.W.) + LN (40 mg/kg B.W.) simultaneously administered and V, LN (40 mg/kg b.w.). The result showed that simultaneous treatment with linalool significantly reduces AST, ALT and ALP activities compared to the IMTB group. Moreover, linalool abrogated IMTB-induced increase in advanced oxidation protein products and abated IMTB-facilitated surge decrease in total thiol levels and arylesterase activity. Additionally, linalool prevented pathological lesions and imatinib-induced necrotic influence in the liver of co-treated mice. Overall, linalool abrogative influence improved liver damage occasioned by IMTB-mediated toxicities in mice by alleviating oxidative stress resulting from imatinib administration.
No takes yet. Share an insight, caveat, or question.
Ola et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: